Closed Loop Medicine appoints Kate Woolland as Chief Operating Officer

Closed Loop Medicine Ltd., a leading TechBio company developing combination prescription drug plus software therapy products that enable personalized dose optimization, today announced that it has appointed Kate Woolland as Chief Operating Officer. Kate joins CEO, Dr. Hakim Yadi PhD OBE, on the executive team to guide organizational and operational delivery of the Company’s lead programs, products and commercial partnerships.

Kate’s appointment follows Closed Loop Medicine’s recent announcement of a co-development partnership deal with Pharmanovia, a global lifecycle management healthcare company, for drug plus software product solutions for the treatment of hypertension (1). Bringing extensive strategic business experience, including over 13 years in healthcare, Kate strengthens the executive team and supports the Company as it continues to scale commercial development. As COO, she will play a pivotal role in leading collaboration across the multi-disciplinary team whilst working closely with current and future commercial partners to drive delivery of Closed Loop Medicine’s products to market.

In her previous role, Kate was Chief Delivery Officer at ieso Digital Health, where she led product, design, clinical trial operations, commercial, regulatory and program management functions. During that time, Kate secured ieso’s first commercial partnerships and launched its first medical device; demonstrating capability that helped secure $53m Series B investment. Prior to this, Kate was a Partner for PA Consulting, during which time she supported the development of numerous commercial partnerships and built a healthcare system transformation consulting business worth over £10m p.a. She holds a Masters in Mathematics from The University of Manchester.

Kate Woolland, COO of Closed Loop Medicine, added: I am thrilled to join the Closed Loop Medicine team at such an exciting stage. Leveraging the capabilities of our incredible technologies to revolutionize the dosing of medicines has the potential to help patients and healthcare professionals better manage health conditions, improve quality of life and health outcomes for millions of people. I am delighted to have the opportunity to play a part in such ground-breaking work.”

Dr. Hakim Yadi PhD OBE, CEO & Co-Founder of Closed Loop Medicine, commented: “As Chief Operating Officer, Kate brings a wealth of experience in optimizing and improving health systems and helping scale next generation digitally delivered health services from her time at ieso. We are on a mission to provide the right dose of medicine to patients and are excited to have Kate join us on this journey, helping build and develop our team dedicated to dose optimization and combination products.”


Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Closed Loop Medicine. (2023, June 20). Closed Loop Medicine appoints Kate Woolland as Chief Operating Officer. News-Medical. Retrieved on June 18, 2024 from

  • MLA

    Closed Loop Medicine. "Closed Loop Medicine appoints Kate Woolland as Chief Operating Officer". News-Medical. 18 June 2024. <>.

  • Chicago

    Closed Loop Medicine. "Closed Loop Medicine appoints Kate Woolland as Chief Operating Officer". News-Medical. (accessed June 18, 2024).

  • Harvard

    Closed Loop Medicine. 2023. Closed Loop Medicine appoints Kate Woolland as Chief Operating Officer. News-Medical, viewed 18 June 2024,


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.